Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects

AIMS: This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 antibody TAK‐079. METHODS: A randomised, double‐blind, placebo‐controlled trial of a single intravenous (i.v.) infusion or subcutaneous (s.c.) injection of TAK‐079 at escalating doses in healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedyk, Eric R., Zhao, Lin, Koch, Annelize, Smithson, Glennda, Estevam, Jose, Chen, Grace, Lahu, Gezim, Roepcke, Stefan, Lin, Jianchang, Mclean, Lachy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319013/
https://www.ncbi.nlm.nih.gov/pubmed/32045493
http://dx.doi.org/10.1111/bcp.14241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319013/
https://www.ncbi.nlm.nih.gov/pubmed/32045493
http://dx.doi.org/10.1111/bcp.14241

Ejemplares similares